IL291396B1 - Mll1 inhibitors and anti-cancer agents - Google Patents

Mll1 inhibitors and anti-cancer agents

Info

Publication number
IL291396B1
IL291396B1 IL291396A IL29139622A IL291396B1 IL 291396 B1 IL291396 B1 IL 291396B1 IL 291396 A IL291396 A IL 291396A IL 29139622 A IL29139622 A IL 29139622A IL 291396 B1 IL291396 B1 IL 291396B1
Authority
IL
Israel
Prior art keywords
amino
methyl
purin
carboxamide
cyclopropylpyrrolidine
Prior art date
Application number
IL291396A
Other languages
Hebrew (he)
Other versions
IL291396A (en
IL291396B2 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL291396A publication Critical patent/IL291396A/en
Publication of IL291396B1 publication Critical patent/IL291396B1/en
Publication of IL291396B2 publication Critical patent/IL291396B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (21)

291396/ - 121 - CLAIMS
1. A compound of Formula (I) (I) or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein: A is N; R is H; or R and R together with NH forms a 5-8 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S as ring members; wherein said 5-8 membered heterocyclyl is unsubstituted or substituted by an oxo substituent; R is selected from the group consisting of: (i) -C1-6 alkyl, -haloC1-6 alkyl, -hydroxyC1-6 alkyl, -C1-6alkoxyC1-6alkyl or -C3-8 cycloalkoxy(C1-alkyl); (ii) cyano, -cyanoC1-6 alkyl, -C1-6 alkylthioC1-6alkyl, -C2-6 alkenyl, -haloC2-6 alkenyl, -C2-6 alkynyl, -C1-4 alkyl-S-C1-4alkyl, -C1-4 alkylSO2C1-4alkyl, -SO2(1-4 alkyl) or -C(C1-4 alkyl)=N-O(C1- 4 alkyl); (iii) -C1-4alkylcarbonyl, -(CRaRb)p-C(=O)-OR10a or -C(=O)-(CRaRb)qR; wherein R is C3-7 cycloalkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, each of which is independently unsubstituted or substituted with -C1-6 alkyl or -C1-6 alkoxy; and said 5-6 membered heterocyclyl or 5-6 membered heteroaryl independently comprises 1-3 heteroatoms selected from nitrogen, oxygen and sulfur; (iv) -(CRaRb)r-C(=O)-NRR -(CRaRb)s-NRR, -(CRaRb)1-4-O-(CRaRb)1-4-OR10a or -(CRaRb)1-4-O-(CRaRb)1-4-C(=O)-NRR; wherein R is hydrogen or -C1-6 alkyl; R is hydrogen, -C1-6 alkyl, -C1-6alkoxyC1-6alkyl, -cyanoC1-6 alkyl; -C1-4 alkylSO2R10b wherein R10b is C1-6 alkyl or phenyl; C3-10 monocylic or bicyclic cycloalkylC0-6alkyl, phenyl, 5-10 membered monocyclic or bicyclic heterocyclic ring or 5-membered heteroarylC0-6alkyl; 291396/ - 122 - said 5-10 membered monocyclic or bicyclic heterocyclic ring or 5-9 membered heteroaryl radical independently comprises 1-4 heteroatoms selected from nitrogen, oxygen and sulfur; and said C3-10 monocylic or bicyclic cycloalkyl, phenyl, 5-10 membered monocyclic or bicyclic heterocyclic ring or 5-9 membered heteroaryl radical are independently unsubstituted or substituted with 1-2 -C1-4 alkyl, -hydroxyC1-6 alkyl, -C1-4 alkoxy, halo, hydroxyl, phenyl or -S(C1-4 alkyl); or R and R together form a 5-10 membered monocyclic or bicyclic heterocyclic ring comprising 1-4 heteroatoms selected from nitrogen, oxygen and sulfur; and is unsubstituted or substituted with -C1-4 alkyl, hydroxyl, cyano, -cyanoC1-6 alkyl, -SO2 or -C2-4alkenylcarbonyl; (v) 5-6 membered heterocyclylC0-6alkyl or 5-6 membered heterocyclyl(haloC1-4 alkyl) wherein each said heterocyclyl radical is unsubstituted or substituted by oxo; and wherein each said heterocyclyl radical comprises 1-3 heteroatoms selected from nitrogen, oxygen and sulfur; and (vi) phenyl, 5-9 membered heteroarylC0-6alkyl or 5-9 membered heteroaryl(haloC1-4alkyl), wherein each said phenyl or heteroaryl radical is independently unsubstituted or substituted by -C1-4 alkyl, -haloC1-4 alkyl, -hydroxyC1-4 alkyl, -C1-4 alkoxy, -haloC1-4 alkoxy, halo, hydroxy, cyano, oxido, amino, -C1-4 alkylamino, -C1-4 dialkylamino, -aminocarbonylC0-6alkyl, -C1-4alkylaminocarbonylC0-6alkyl, -diC1-4alkylaminocarbonylC0-6alkyl or C3-7 cycloalkyl; wherein each said heteroaryl radical comprises 1-4 heteroatoms selected from nitrogen, oxygen and sulfur; R3a, R3b, R4a, R4b, R5a, R5b, R6a and R6b are independently hydrogen, halo, cyano, hydroxyl, -C1-6 alkyl, -haloC1-6 alkyl, -hydroxyC1-6 alkyl, -C1-6 alkoxy, -C1-6alkoxyC1-6alkyl, aryl, -C(=O)-OR or -(CRaRb)s-C(=O)-NRR; or R3a and R3b, R4a and R4b, R5a and R5b or R6a and R6b forms an oxo substituent; R, R, R and R are independently hydrogen, halo, -C1-4 alkyl, -haloC1-6 alkyl, -hydroxyC1-alkyl, cyano, -cyanoC1-6 alkyl, -C2-6 alkenyl, -C2-6 alkynyl, -C1-6 alkylthio, -(CRaRb)1-4-NRR, -(CRaRb)1-4NR-C(O)-OR, -(CRaRb)1-4–OR, C3-8 cycloalkyl, phenyl or 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from nitrogen, oxygen and sulfur; wherein said C3-8 cycloalkyl, phenyl or 5-6 membered heteroaryl is independently substituted with 1-2 R; and provided at least one of R, R, R and Ris not hydrogen; alternatively, R and R, R and R, and R together with the phenyl ring to which they are attached form a 9-10 membered benzo-fused carbocycle or benzo-fused heterocycle comprising 1-3 heteroatoms selected from nitrogen, oxygen and sulfur; wherein said benzo- fused carbocycle or benzo-fused heterocycle is independently unsubstituted or substituted with 1-2 halo or C1-4 alkyl; Ra, Rb, R10a, R, R, R and R are independently hydrogen or -C1-4 alkyl; 291396/ - 123 - R is hydrogen, -C1-4 alkyl, -haloC1-6 alkyl or -C3-6 cycloalkyl; alternatively, R and R together with N in the -NRR moiety form a 4-10 membered monocyclic or bicyclic heterocyclic ring comprising 1-3 heteroatoms selected from nitrogen, oxygen and sulfur; wherein said 4-10 membered monocyclic or bicyclic heterocyclic ring is unsubstituted or substituted with 1-2 halo or C1-4 alkyl; R is hydrogen, -C1-4 alkyl, -haloC1-6 alkyl, -C3-6 cycloalkyl, phenyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl; wherein said 5-6 membered heterocyclyl or 5-membered heteroaryl independently comprises 1-3 heteroatoms selected from nitrogen, oxygen and sulfur; R is -C1-4 alkyl, -halo or -C3-6 cycloalkyl; or two R together form a 5-6 membered ring comprising 0-2 heteroatoms selected from nitrogen, oxygen and sulfur; n is 0 or 1; and p, q, r, s and t are independently 0, 1, 2, 3 or 4.
2. The compound of Formula (I) in claim 1, wherein said compound is a compound of Formula (II): (II) or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein: R is selected from the group consisting of: (i) -hydroxyC1-6 alkyl, -C1-6alkoxyC1-6alkyl or -(CRaRb)p-C(=O)-OR10a; (ii) -(CRaRb)r-C(=O)-NRR or -(CRaRb)1-4-O-(CRaRb)1-4-C(=O)-NRR; wherein R is hydrogen or -C1-6 alkyl; R is hydrogen, -C1-6 alkyl, -cyanoC1-6 alkyl; -C1-4 alkylSO2R10b wherein R10b is -C1-6 alkyl or phenyl; C3-10 monocylic or bicyclic cycloalkylC0-6alkyl, phenyl, 5-10 membered monocyclic or bicyclic heterocyclic ring or 5-9 membered heteroarylC0-6alkyl; wherein said 5-10 membered monocyclic or bicyclic heterocyclic ring or 5-9 membered heteroaryl radical independently comprises 1-4 heteroatoms selected from nitrogen, oxygen and sulfur; and 291396/ - 124 - said C3-10 monocylic or bicyclic cycloalkyl, phenyl, 5-10 membered monocyclic or bicyclic heterocyclic ring or 5-9 membered heteroaryl radical are independently unsubstituted or substituted with 1-2 -C1-4 alkyl, -hydroxyC1-6 alkyl, -C1-4 alkoxy, halo, hydroxyl, phenyl or -S(C1-4 alkyl); or R and R together form a 5-10 membered monocyclic or bicyclic heterocyclic ring comprising 1-4 heteroatoms selected from nitrogen, oxygen and sulfur; and is unsubstituted or substituted with -C1-4 alkyl, hydroxyl, cyano, -cyanoC1-6 alkyl, -SO2 or -C2-4alkenylcarbonyl; and (iii) phenyl or 5-9 membered heteroarylC0-6alkyl; wherein said heteroaryl radical is unsubstituted or substituted by -C1-4 alkyl, -haloC1-4 alkyl, amino, -C1-4 alkylamino or -C1-dialkylamino; and said heteroaryl radical comprises 1-4 heteroatoms selected from nitrogen, oxygen and sulfur; R, R, R and R are independently hydrogen, halo, -C1-4 alkyl, -haloC1-6 alkyl, -hydroxyC1-alkyl, cyano, -cyanoC1-6 alkyl, -C2-6 alkenyl, -C2-6 alkynyl, -C1-6 alkylthio, -(CRaRb)1-4-NRR, -(CRaRb)1-4NR-C(O)-OR, -(CRaRb)1-4–OR, -C 3-8 cycloalkyl, phenyl or 5-6 membered heteroaryl comprising 1-4 heteroatoms selected from nitrogen, oxygen and sulfur; and wherein said C3-8 cycloalkyl, phenyl or 5-6 membered heteroaryl is independently substituted with 1-2 R; and provided at least one of R, R, R and Ris not hydrogen; alternatively, R and R, R and R, R and R together with the phenyl ring to which they are attached form a 9-10 membered benzo-fused carbocycle or benzo-fused heterocycle comprising 1-3 heteroatoms selected from nitrogen, oxygen and sulfur; wherein said benzo-fused carbocycle or benzo-fused heterocycle is independently unsubstituted or substituted with 1-2 halo or -C1-4 alkyl; Ra, Rb, R10a and R are independently hydrogen or -C1-4 alkyl; R is hydrogen, -C1-4 alkyl, -haloC1-6 alkyl or -C3-6 cycloalkyl; alternatively, R and R together with N in the -NRR moiety form a 4-10 membered monocyclic or bicyclic heterocyclic ring comprising 1-3 heteroatoms selected from nitrogen, oxygen and sulfur; wherein said heterocyclic ring is unsubstituted or substituted with 1-2 halo or -C1-4 alkyl; R is hydrogen, -C1-4 alkyl, -haloC1-6 alkyl, -C3-6 cycloalkyl, phenyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl; wherein said 5-6 membered heterocyclyl or 5-membered heteroaryl independently comprises 1-3 heteroatoms selected from nitrogen, oxygen and sulfur; R is -C1-4 alkyl, halo or -C3-6 cycloalkyl; or two R together form a 5-6 membered ring comprising 0-2 heteroatoms selected from nitrogen, oxygen and sulfur; n is 0 or 1; and p, q, r, s and t are independently 0, 1, 2, 3 or 4. 291396/ - 125 -
3. The compound of Formula (II) in claim 2, wherein said compound is a compound of Formula (III): (III) or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof.
4. The compound of Formula (III) in claim 3, wherein said compound is a compound of Formula (IV): (IV) or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof.
5. The compound of any one of claims 1-4 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R is , , , , or .
6. The compound of any one of claims 1-4 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R is, , or . 291396/ - 126 -
7. The compound of any one of claims 1-4 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R is , , or .
8. The compound of any one of claims 1-4 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R is , , , 1H- tetrazolyl, 2H-tetrazoly, pyridyl, trifluoromethylpyridyl or phenyl.
9. The compound of any one of claims 1-4 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein said compound is a compound of Formula (V): (V)
10. The compound of any one of claims 1-9 or a pharmaceutically acceptable salt thereof; wherein at least two of R, R, R and Rare not hydrogen.
11. The compound of claim 10 or a pharmaceutically acceptable salt thereof; wherein R, R, R and Rare independently hydrogen, halo, -C1-4alkyl, -haloC1-6 alkyl, -hydroxyC1-6 alkyl, -C2-alkenyl, -C3-8 cycloalkyl, -(CRaRb)1-4-NRR, or -(CRaRb)1-4–OR; provided at least two of R, R, R and Rare not hydrogen; Ra, Rb and R are independently hydrogen or -C1-4 alkyl; R is hydrogen, -C1-4 alkyl, -haloC1-6 alkyl or -C3-6 cycloalkyl; alternatively, R and R together with N in the -NRR moiety form a 4-10 membered monocyclic or bicyclic heterocyclic ring comprising 1-3 heteroatoms selected from nitrogen, oxygen and sulfur; wherein said heterocyclic ring is unsubstituted or substituted with 1-2 halo or -C1-4 alkyl; and 291396/ - 127 - R is hydrogen, -C1-4 alkyl, -haloC1-6 alkyl, -C3-6 cycloalkyl, phenyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl; wherein said 5-6 membered heterocyclyl or 5-membered heteroaryl independently comprises 1-3 heteroatoms selected from nitrogen, oxygen and sulfur.
12. The compound of any one of claims 1-4 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein said compound is a compound of Formula (V): (V) wherein R, R, R and Rare independently hydrogen, halo, -haloC1-6 alkyl, provided at least two of R, R, R and Rare not hydrogen.
13. The compound according to claim 1 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein said compound is selected from thefollowing compounds, or a pharmaceutically acceptable salt thereof: (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-5-chlorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-3-ethylphenyl)-N- cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-3-(2,3-dihydrobenzofuran-5-yl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-cyano-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-ethynyl-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(2,2,2-trifluoroethyl)phenyl) –N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-3-(2,2,2-trifluoroethyl)phenyl)-N- cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-cyclopropyl-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, 291396/ - 128 - 3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-vinylphenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-ethyl-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-methyl-4-(trifluoromethyl)phenyl)-N- cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-ethyl-4-(trifluoromethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-3’-cyclohexyl-[1,1’-biphenyl]-3- yl)pyrrolidine-3-carboxamide, (R)-1-(4-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-ethyl-4-fluorophenyl)pyrrolidine-3-carbonyl)piperazin-1-yl)prop-2-en-1-one, (R)-9-(2-(3-amino-3-(1H-1,2,4-triazol-3-yl)pyrrolidin-1-yl)-6-bromo-4-chlorobenzyl)-9H-purin-6-amine, (R)-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-5-chlorophenyl)pyrrolidin-3-yl)methanol, (R)-3-amino-1-(6-((6-amino-9H-purin-9-yl)methyl)-5-bromo-4-fluoro-2,3-dihydrobenzofuran-7-yl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-6-methoxyphenyl )-N- cyclopropylpyrrolidine-3-carboxamide, 9-(6-(3-amino-3-(pyridin-2-yl)pyrrolidin-1-yl)-3-fluoro-2-(trifluoromethyl)benzyl)-9H-purin-6-amine, (R)-9-(6-(3-amino-3-(pyridin-2-yl)pyrrolidin-1-yl)-3-fluoro-2-(trifluoromethyl)benzyl)-9H-purin-6-amine, (R)-9-(2-(3-amino-3-(1H-1,2,4-triazol-3-yl)pyrrolidin-1-yl)-4-chloro-6-vinylbenzyl)-9H-purin-6-amine, 291396/ - 129 - (R)-9-(2-(3-amino-3-(1H-1,2,4-triazol-3-yl)pyrrolidin-1-yl)-4-chloro-6-ethylbenzyl)-9H-purin-6-amine, (S)-9-(6-(3-amino-3-phenylpyrrolidin-1-yl)-3-fluoro-2-(trifluoromethyl)benzyl)-9H-purin-6-amine, (R)-9-(2-(3-amino-3-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-1-yl)-6-bromo-4-chlorobenzyl)- 9H-purin-6-amine, (R)-9-(6-(3-amino-3-(2-(pyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-fluoro-2-(trifluoromethyl)benzyl)-9H-purin-6-amine, methyl (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-3-cyclobutylphenyl)pyrrolidine-3-carboxylate, (R)-2-((3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-5-chlorophenyl)pyrrolidin-3-yl)methoxy)-N-cyclopropylacetamide, 3-amino-1-(5-((6-amino-9H-purin-9-yl)methyl)-6-bromobenzo[d][1,3]dioxol-4-yl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-9-(2-(3-amino-3-(methoxymethyl)pyrrolidin-1-yl)-6-bromo-4-chlorobenzyl)-9H-purin-6- amine, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-3-((R)-2,2,2-trifluoro-1-hydroxyethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, ethyl (R)-3-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-5-chlorophenyl)pyrrolidin-3-yl) propanoate, (R)-5-(2-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-3-ethylphenyl)pyrrolidin-3-yl)ethyl)-N-methyl-1,3,4-thiadiazol-2-amine, (R)-3-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-5-chlorophenyl)pyrrolidin-3-yl)-N-ethylpropanamide, 3-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-5-chlorophenyl)pyrrolidin-3- yl)propanamide, (R)-3-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-3-ethylphenyl)pyrrolidin-3-yl)-N-ethylpropanamide, (R)-9-(2-(3-(2-(2H-tetrazol-5-yl)ethyl)-3-aminopyrrolidin-1-yl)-6-bromo-4-chlorobenzyl)-9H-purin-6-amine, (R)-9-(2-(3-(2-(2H-tetrazol-5-yl)ethyl)-3-aminopyrrolidin-1-yl)-4-chloro-6-ethylbenzyl)-9H-purin-6-amine, 291396/ - 130 - (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-4-(trifluoromethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, 3-amino-1-(5-((6-amino-9H-purin-9-yl)methyl)-6-bromo-7-chloro-2,3-dihydro-1H-inden-4-yl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-5,6-dichlorophenyl)-N- cyclopropylpyrrolidine-3-carboxamide, 3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-4,5,6-trichlorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-((dimethylamino)methyl)-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(piperidin-1-ylmethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-((dimethylamino)methyl)-4-(trifluoromethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-((cyclopropyl(methyl)amino)methyl)-4- fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-((dimethylamino)methyl)-4-fluorophenyl)-N-((1S,2R)-2-phenylcyclopropyl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(((R)-3-fluoropyrrolidin-1-yl)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(morpholinomethyl)phenyl)-N-((1S,2R)-2-phenylcyclopropyl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-((3,3-difluoroazetidin-1-yl)methyl)-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-((3-fluoroazetidin-1- yl)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-((cyclopropylamino)methyl)-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-((4,4-difluoropiperidin-1-yl)methyl)-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-((4-fluoropiperidin-1-yl)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, 291396/ - 131 - (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(((2,2,2-trifluoroethyl)amino)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (3R)-1-(3-((8-oxa-3-azabicyclo[3.2.1]octan-3-yl)methyl)-2-((6-amino-9H-purin-9-yl)methyl)-4-fluorophenyl)-3-amino-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-((cyclopropyl(ethyl)amino)methyl)-4- fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-((dimethylamino)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(pyrrolidin-1-ylmethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-(azetidin-1-ylmethyl)-4-(trifluoromethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-((3,3-dimethylpyrrolidin-1-yl)methyl)-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-((3-methylazetidin-1- yl)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(morpholinomethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-((3,3-difluoropyrrolidin-1-yl)methyl)-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-((diethylamino)methyl)-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(((S)-3-fluoropyrrolidin-1-yl)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-((3,3-difluoropiperidin-1-yl)methyl)-4- fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-(azetidin-1-ylmethyl)-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, methyl (R)-(3-(3-amino-3-(cyclopropylcarbamoyl)pyrrolidin-1-yl)-2-((6-amino-9H-purin-9-yl)methyl)-6-fluorobenzyl)carbamate, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-6-chloro-3-((dimethylamino)methyl)-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, 291396/ - 132 - (R)-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4,6-dichloro-3-ethylphenyl)pyrrolidin-3-yl)(1,1-dioxidothiomorpholino)methanone, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4,6-dichloro-3-((dimethylamino)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-6-chloro-4-fluoro-3- (morpholinomethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(hydroxymethyl) phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(methoxymethyl) phenyl)-N-cyclopropylpyrrolidine-3-carboxamide , (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-(methoxymethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (3R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-(((tetrahydrofuran-3-yl)oxy)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-((methoxy-d3)methyl)phenyl)-N- cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-((methoxy-d3)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-((S)-2,2,2-trifluoro-1-hydroxyethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide , (R)-9-(2-(3-amino-3-(1H-tetrazol-5-yl)pyrrolidin-1-yl)-6-bromo-4-chlorobenzyl)-9H-purin-6-amine, (R)-9-((3-(3-amino-3-(2H-tetrazol-5-yl)pyrrolidin-1-yl)-5-chloro-3'-cyclohexyl-[1,1'-biphenyl]-2-yl)methyl)-9H-purin-6-amine, (R)-9-(6-(3-amino-3-(1H-1,2,4-triazol-3-yl)pyrrolidin-1-yl)-2,3-dichlorobenzyl)-9H-purin-6- amine, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-((difluoromethoxy)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-4-(trifluoromethyl)phenyl)-N-(2-cyanoethyl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4,5-dichloro-3-((dimethylamino)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, 291396/ - 133 - (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5,6-dichloro-3-((dimethylamino)methyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-9-(2-(3-amino-3-(1-methyl-1H-tetrazol-5-yl)pyrrolidin-1-yl)-6-bromo-4-chlorobenzyl)-9H-purin-6-amine, (R)-9-(2-(3-amino-3-(2-methyl-2H-tetrazol-5-yl)pyrrolidin-1-yl)-6-bromo-4-chlorobenzyl)-9H- purin-6-amine, (R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-5-ethyl-2'-fluoro-[1,1'-biphenyl]-3-yl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-ethyl-5-(thiophen-2-yl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-(thiophen-2-yl)-3-(trifluoromethyl) phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-ethyl-5-(pyridin-3-yl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-ethyl-5-(1-methyl-1H-pyrazol-4- yl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, 3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-cyclopropylphenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-ethyl-5-(thiazol-4-yl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-ethyl-5-(pyridin-2-yl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-ethyl-5-(pyrazin-2-yl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-4-cyano-3-ethylphenyl)-N- cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-4-fluoro-3-(morpholinomethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide , (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-chloro-4-fluoro-5-(morpholinomethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide , (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-cyanophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, 291396/ - 134 - (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4,5-dichloro-3-(morpholinomethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (S)-(3-amino-1-(1-((6-amino-9H-purin-9-yl)methyl)naphthalen-2-yl)pyrrolidin-3-yl)methanol, (S)-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-5-chlorophenyl)pyrrolidin-3-yl)methanol, (R)-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-3-ethylphenyl)pyrrolidin-3-yl)methanol, (R)-9-((2-(3-amino-3-(methoxymethyl)pyrrolidin-1-yl)naphthalen-1-yl)methyl)-9H-purin-6-amine , (R)-3-amino-1-(6-((6-amino-9H-purin-9-yl)methyl)-5-bromo-4-chloro-2,3-dihydrobenzofuran- 7-yl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(6-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-5-iodo-2,3-dihydrobenzofuran-7-yl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(7-((6-amino-9H-purin-9-yl)methyl)benzofuran-6-yl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-(ethylthio)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(7-((6-amino-9H-purin-9-yl)methyl)-2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)-N-cyclopropylpyrrolidine-3-carboxamide, 3-amino-1-(5-((6-amino-9H-purin-9-yl)methyl)-6-bromo-2,3-dihydrobenzofuran-4-yl)-N- cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-((1r,3R)-3-(methylthio)cyclobutyl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-(pyridazin-3-ylmethyl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-(2-cyano-2-methylpropyl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-((2- hydroxypyridin-3-yl)methyl)pyrrolidine-3-carboxamide, (R)-N-(2-(1H-imidazol-4-yl)ethyl)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide, 291396/ - 135 - (3R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-((2,2-difluorocyclopropyl)methyl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-((R)- 1-(tetrahydro-2H-pyran-4-yl)ethyl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-(2-cyano-2-methylpropyl)pyrrolidine-3-carboxamide, (3R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-(6-oxaspiro[2.5]octan-1-yl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-((1R,2R)-2-(hydroxymethyl)cyclopropyl)pyrrolidine-3-carboxamide, (R)-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)pyrrolidin-3-yl)(6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-5(4H)-yl)methanone, (3R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-(tetrahydrofuran-3-yl)pyrrolidine-3-carboxamide, (3R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-(5-methoxyspiro[2.3]hexan-1-yl)pyrrolidine-3-carboxamide, ((R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3- (trifluoromethyl)phenyl)pyrrolidin-3-yl)((S)-2-methylmorpholino)methanone, (R)-1-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)pyrrolidine-3-carbonyl)azetidine-3-carbonitrile, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-((2-aminopyrimidin-4-yl)methyl)pyrrolidine-3-carboxamide,, (R)-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)pyrrolidin-3-yl)(6,7-dihydroisoxazolo[4,3-c]pyridin-5(4H)-yl)methanone, ((R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)pyrrolidin-3-yl)((R)-2-methylmorpholino)methanone, (R)-2-(4-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3- (trifluoromethyl)phenyl)pyrrolidine-3-carbonyl)piperazin-1-yl)acetonitrile, (R)-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)pyrrolidin-3-yl)(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)methanone, 291396/ - 136 - ((R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)pyrrolidin-3-yl)((R)-3-hydroxypiperidin-1-yl)methanone, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-(3-oxo-3-(propylamino)propyl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)-N-((1- ethyl-1H-1,2,4-triazol-5-yl)methyl)pyrrolidine-3-carboxamide, 1-((R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-fluoro-3-(trifluoromethyl)phenyl)pyrrolidine-3-carbonyl)pyrrolidine-3-carbonitrile, (S)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-6-chlorophenyl)pyrrolidine-3-carboxylic acid, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-4,6-dichlorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3,4-dichlorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-ethylphenyl)-N-(2- (phenylsulfonyl)ethyl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-bromo-3-(trifluoromethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-4-(trifluoromethoxy)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-5-chlorophenyl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-ethylphenyl)-N-(2-(ethylsulfonyl)ethyl)pyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-3-(5,6,7,8-tetrahydronaphthalen- 1-yl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-3-ethylphenyl)pyrrolidin-3-yl)(1,1-dioxidothiomorpholino)methanone,, 3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3,4-dichloro-6-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-ethylphenyl)-N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)pyrrolidine-3-carboxamide, 291396/ - 137 - (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-6-chloro-3-ethylphenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-(3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-ethylphenyl)pyrrolidin-3-yl)(1,1-dioxidothiomorpholino)methanone, (R)-9-(6-(3-amino-3-(1H-tetrazol-5-yl)pyrrolidin-1-yl)-3-chloro-2-iodobenzyl)-9H-purin-6- amine, 3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-chloro-6-methylphenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-cyclopentyl-4-fluorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-5-chlorophenyl)-N-(ethyl-d5)pyrrolidine-3-carboxamide, 3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-chloro-4-(trifluoromethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-5-chloro-3-ethylphenyl)-N- isopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4,6-dichloro-3-(methoxymethyl)phenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-vinylphenyl)-N-cyclopropylpyrrolidine-3-carboxamide, 3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-chlorophenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-4-chloro-3-ethylphenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (S)-3-amino-1-(1-((6-amino-9H-purin-9-yl)methyl)naphthalen-2-yl)-N-cyclopropylpyrrolidine- 3-carboxamide, (R)-3-amino-1-(1-((6-amino-9H-purin-9-yl)methyl)-6-bromonaphthalen-2-yl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-4-methoxyphenyl)-N-cyclopropylpyrrolidine-3-carboxamide, (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-ethylphenyl)-N-cyclopentylpyrrolidine-3-carboxamide, 291396/ - 138 - ethyl (R)-3-amino-1-(2-((6-amino-9H-purin-9-yl)methyl)-3-bromo-5-chlorophenyl)pyrrolidine-3-carboxylate.
14. A pharmaceutical composition comprising a compound according to any one of claims 1-13 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carrier.
15. A combination comprising a compound according to any one of claims 1-13 or a pharmaceutically acceptable salt thereof, and one or more therapeutically active agent.
16. The combination according to claim 15, wherein said one or more therapeutically active agent is an anti-cancer agent, an analgesic or an anti-inflammatory agent.
17. A compound according to any one of claims 1-13 or a pharmaceutically acceptable salt thereof, a composition according to claim 14, or a combination according to any of claims 15-for use in a method for treating a disease or condition that benefit from or is treatable by inhibition of mixed lineage leukemia 1 (MLL1).
18. The compound, composition, or combination for use of claim 17, wherein said disease or condition that benefit from or is treatable by inhibition of MLL1 is selected from solid tumors, leukemia, myeloma, lymphoma and hypertension.
19. The compound, composition, or combination for use of claim 17, wherein said disease or condition that benefit from or is treatable by inhibition of MLL1 is breast cancer, cervical cancer, skin cancer, ovarian cancer, gastric cancer, prostate cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, head and neck cancer, peripheral nerve sheath tumor, osteosarcoma, multiple myeloma, neuroblastoma, leukemia, non-Hodgkin’s lymphoma or pulmonary arterial hypertension.
20. The compound, composition, or combination for use of claim 19, wherein said disease or condition that benefit from or is treatable by inhibition of MLL1 is leukemia, skin cancer or lymphoma; wherein said leukemia is acute lymphoblastic leukemia; said skin cancer is skin squamous cell carcinoma; and said lymphoma is mantle cell lymphoma.
21. A compound according to any one of claims 1-13 and optionally in combination with a second therapeutic agent, for use in the manufacture of a medicament for a disease or condition that benefit from or is treatable by inhibition of mixed lineage leukemia 1 (MLL1).
IL291396A 2019-09-20 2020-09-18 Mll1 inhibitors and anti-cancer agents IL291396B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019107010 2019-09-20
CN2020095916 2020-06-12
PCT/IB2020/058735 WO2021053617A1 (en) 2019-09-20 2020-09-18 Mll1 inhibitors and anti-cancer agents

Publications (3)

Publication Number Publication Date
IL291396A IL291396A (en) 2022-05-01
IL291396B1 true IL291396B1 (en) 2025-10-01
IL291396B2 IL291396B2 (en) 2026-02-01

Family

ID=72659833

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291396A IL291396B2 (en) 2019-09-20 2020-09-18 Mll1 inhibitors and anti-cancer agents

Country Status (11)

Country Link
US (1) US20220380371A1 (en)
EP (1) EP4013756B1 (en)
JP (1) JP7344372B2 (en)
KR (1) KR102779693B1 (en)
CN (1) CN114981270B (en)
AU (1) AU2020350211B2 (en)
CA (1) CA3154136C (en)
DK (1) DK4013756T3 (en)
ES (1) ES2987269T3 (en)
IL (1) IL291396B2 (en)
WO (1) WO2021053617A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025504379A (en) 2022-01-05 2025-02-12 ケイ36・セラピューティクス・インコーポレイテッド Deuterium-enriched piperidinyl-methyl-purinamine and related compounds and their use in treating diseases and conditions - Patents.com
CN116425685A (en) * 2023-04-18 2023-07-14 安徽联创生物医药股份有限公司 A kind of synthetic method of elagolix sodium impurity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1550662A1 (en) * 2002-09-27 2005-07-06 Sumitomo Pharmaceuticals Company, Limited Novel adenine compound and use thereof
WO2015002754A2 (en) * 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors
WO2016195776A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2018053267A1 (en) * 2016-09-16 2018-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144675A0 (en) * 1999-02-01 2002-05-23 Cv Therapeutics Inc PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1550662A1 (en) * 2002-09-27 2005-07-06 Sumitomo Pharmaceuticals Company, Limited Novel adenine compound and use thereof
WO2015002754A2 (en) * 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors
WO2016195776A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2018053267A1 (en) * 2016-09-16 2018-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction

Also Published As

Publication number Publication date
EP4013756B1 (en) 2024-05-08
IL291396A (en) 2022-05-01
US20220380371A1 (en) 2022-12-01
CN114981270B (en) 2024-10-18
JP2022548618A (en) 2022-11-21
JP7344372B2 (en) 2023-09-13
KR20220050963A (en) 2022-04-25
ES2987269T3 (en) 2024-11-14
AU2020350211B2 (en) 2023-08-17
CA3154136A1 (en) 2021-03-25
IL291396B2 (en) 2026-02-01
DK4013756T3 (en) 2024-05-27
CN114981270A (en) 2022-08-30
AU2020350211A1 (en) 2022-04-07
KR102779693B1 (en) 2025-03-12
WO2021053617A1 (en) 2021-03-25
EP4013756A1 (en) 2022-06-22
CA3154136C (en) 2025-05-06

Similar Documents

Publication Publication Date Title
US11780845B2 (en) FGFR inhibitors and methods of use thereof
JP7550870B2 (en) Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US20250122222A1 (en) Heterocyclic compounds and methods of use
JP7860103B2 (en) Heterocyclic spiro compounds and methods for using them
JP2022531801A5 (en)
US10898481B2 (en) Pyrazine compounds and uses thereof
US20250059205A1 (en) Heterocyclic Compounds and Methods of Use
US8791125B2 (en) Dihydropyrazolopyrimidinone derivatives
JP2025533831A (en) Tethered heterocyclic inhibitors of KRAS G12C mutant protein and uses thereof
JP2022544946A5 (en)
US20160060262A1 (en) Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof
FI3436461T3 (en) Pyrrolotriazine compounds as tam inhibitors
US12263171B2 (en) 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
KR20200087132A (en) Combination pharmaceutical preparations as RSV inhibitors
JP2021502356A5 (en)
US20220388964A1 (en) (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions
RU2019120986A (en) PHARMACEUTICAL COMBINATION CONTAINING ALK INHIBITOR AND SHP2 INHIBITOR
CN120677154A (en) N-phenyl-pyrazolo [1,5-a ] pyridine-3-carboxamide derivatives as wild-type C-KIT kinase inhibitors for the treatment of urticaria
JP2019504821A5 (en)
KR20150041787A (en) 2,3-benzodiazepines
US20180148418A1 (en) Amido-substituted cyclohexane derivatives
JP2009538322A5 (en)
MXPA06013996A (en) Fused heterocyclic compound.
WO2015002994A2 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
JP7681116B2 (en) Carbonyl-substituted diazaspiro compounds and uses thereof